ScoreComparison
Why is Day One Biopharmaceuticals, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -34.93% over the last 5 years
2
The company has declared negative results in Jan 70 after 4 consecutive negative quarters
- PRE-TAX PROFIT(Q) At USD -30.32 MM has Fallen at -962.07%
- NET PROFIT(Q) At USD -30.32 MM has Fallen at -588.04%
- DEBT-EQUITY RATIO (HY) Highest at -97.67 %
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -29.73%, its profits have risen by 66.9%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -29.73% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Day One Biopharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Day One Biopharmaceuticals, Inc.
-38.63%
-0.38
65.33%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-34.93%
EBIT Growth (5y)
14.78%
EBIT to Interest (avg)
-128.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.24
Tax Ratio
11.53%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.52
EV to EBIT
-1.34
EV to EBITDA
-1.36
EV to Capital Employed
39.04
EV to Sales
1.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2922.95%
ROE (Latest)
-14.41%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
NET SALES(Q)
At USD 33.91 MM has Grown at 313.92%
OPERATING CASH FLOW(Y)
Highest at USD -63.07 MM
NET PROFIT(HY)
Higher at USD -66.32 MM
-9What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -30.32 MM has Fallen at -962.07%
NET PROFIT(Q)
At USD -30.32 MM has Fallen at -588.04%
DEBT-EQUITY RATIO
(HY)
Highest at -97.67 %
Here's what is working for Day One Biopharmaceuticals, Inc.
Net Sales
At USD 33.91 MM has Grown at 313.92%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -63.07 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for Day One Biopharmaceuticals, Inc.
Pre-Tax Profit
At USD -30.32 MM has Fallen at -962.07%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -30.32 MM has Fallen at -588.04%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at -97.67 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
